- Home
- ZEO vs GOVX Comparison
ZEO vs GOVX Comparison
Compare ZEO & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- GOVX
- Stock Information
- Founded
- ZEO 2005
- GOVX 2001
- Country
- ZEO United States
- GOVX United States
- Employees
- ZEO N/A
- GOVX N/A
- Industry
- ZEO
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- GOVX Health Care
- Exchange
- ZEO NYSE
- GOVX Nasdaq
- Market Cap
- ZEO 25.7M
- GOVX 23.8M
- IPO Year
- ZEO N/A
- GOVX N/A
- Fundamental
- Price
- ZEO $1.78
- GOVX $2.26
- Analyst Decision
- ZEO
- GOVX Strong Buy
- Analyst Count
- ZEO 0
- GOVX 5
- Target Price
- ZEO N/A
- GOVX $14.20
- AVG Volume (30 Days)
- ZEO 2.7M
- GOVX 715.7K
- Earning Date
- ZEO 12-31-2024
- GOVX 11-12-2024
- Dividend Yield
- ZEO N/A
- GOVX N/A
- EPS Growth
- ZEO N/A
- GOVX N/A
- EPS
- ZEO 0.67
- GOVX N/A
- Revenue
- ZEO $95,455,763.00
- GOVX $3,090,161.00
- Revenue This Year
- ZEO N/A
- GOVX N/A
- Revenue Next Year
- ZEO N/A
- GOVX $150.51
- P/E Ratio
- ZEO $2.78
- GOVX N/A
- Revenue Growth
- ZEO N/A
- GOVX N/A
- 52 Week Low
- ZEO $1.05
- GOVX $1.09
- 52 Week High
- ZEO $11.60
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- ZEO 49.38
- GOVX 44.80
- Support Level
- ZEO $1.27
- GOVX $2.17
- Resistance Level
- ZEO $3.05
- GOVX $2.50
- Average True Range (ATR)
- ZEO 0.40
- GOVX 0.17
- MACD
- ZEO 0.01
- GOVX -0.04
- Stochastic Oscillator
- ZEO 29.44
- GOVX 18.33
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.